Accure Therapeutics Awarded a Total of $1.6M in Grants from the Michael J. Fox Foundation and Fonds National De Recherche De Luxembourg to Bring First-in-Class Drug for Parkinson’S Disease to Clinical Trials

Accure Therapeutics announced its receipt of two grants totalling $1.6M for two separate development programs on its drug candidate ACT-02. ACT-02 is a novel asset with disease-modifying potential, inhibiting Prolyl Endopeptidase (PREP), a promising but previously overlooked target in Parkinson’s disease.